Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome

K. Szikszai, Z. Krejcik, J. Klema, N. Loudova, A. Hrustincova, M. Belickova, M. Hruba, J. Vesela, V. Stranecky, D. Kundrat, P. Pecherkova, J. Cermak, A. Jonasova, M. Dostalova Merkerova,

. 2020 ; 12 (10) : . [pub] 20200923

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20021620

Grantová podpora
17-31398A Agentura Pro Zdravotnický Výzkum České Republiky
20-19162S Grantová Agentura České Republiky
00023736 Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: myelodysplastic syndrome (MDS) is a hematopoietic stem cell disorder with an incompletely known pathogenesis. Long noncoding RNAs (lncRNAs) play multiple roles in hematopoiesis and represent a new class of biomarkers and therapeutic targets, but information on their roles in MDS is limited. AIMS: here, we aimed to characterize lncRNAs deregulated in MDS that may function in disease pathogenesis. In particular, we focused on the identification of lncRNAs that could serve as novel potential biomarkers of adverse outcomes in MDS. METHODS: we performed microarray expression profiling of lncRNAs and protein-coding genes (PCGs) in the CD34+ bone marrow cells of MDS patients. Expression profiles were analyzed in relation to different aspects of the disease (i.e., diagnosis, disease subtypes, cytogenetic and mutational aberrations, and risk of progression). LncRNA-PCG networks were constructed to link deregulated lncRNAs with regulatory mechanisms associated with MDS. RESULTS: we found several lncRNAs strongly associated with disease pathogenesis (e.g., H19, WT1-AS, TCL6, LEF1-AS1, EPB41L4A-AS1, PVT1, GAS5, and ZFAS1). Of these, downregulation of LEF1-AS1 and TCL6 and upregulation of H19 and WT1-AS were associated with adverse outcomes in MDS patients. Multivariate analysis revealed that the predominant variables predictive of survival are blast count, H19 level, and TP53 mutation. Coexpression network data suggested that prognosis-related lncRNAs are predominantly related to cell adhesion and differentiation processes (H19 and WT1-AS) and mechanisms such as chromatin modification, cytokine response, and cell proliferation and death (LEF1-AS1 and TCL6). In addition, we observed that transcriptional regulation in the H19/IGF2 region is disrupted in higher-risk MDS, and discordant expression in this locus is associated with worse outcomes. CONCLUSIONS: we identified specific lncRNAs contributing to MDS pathogenesis and proposed cellular processes associated with these transcripts. Of the lncRNAs associated with patient prognosis, the level of H19 transcript might serve as a robust marker comparable to the clinical variables currently used for patient stratification.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021620
003      
CZ-PrNML
005      
20231102133404.0
007      
ta
008      
201125s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12102726 $2 doi
035    __
$a (PubMed)32977510
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Szikszai, Katarina $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
245    10
$a LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome / $c K. Szikszai, Z. Krejcik, J. Klema, N. Loudova, A. Hrustincova, M. Belickova, M. Hruba, J. Vesela, V. Stranecky, D. Kundrat, P. Pecherkova, J. Cermak, A. Jonasova, M. Dostalova Merkerova,
520    9_
$a BACKGROUND: myelodysplastic syndrome (MDS) is a hematopoietic stem cell disorder with an incompletely known pathogenesis. Long noncoding RNAs (lncRNAs) play multiple roles in hematopoiesis and represent a new class of biomarkers and therapeutic targets, but information on their roles in MDS is limited. AIMS: here, we aimed to characterize lncRNAs deregulated in MDS that may function in disease pathogenesis. In particular, we focused on the identification of lncRNAs that could serve as novel potential biomarkers of adverse outcomes in MDS. METHODS: we performed microarray expression profiling of lncRNAs and protein-coding genes (PCGs) in the CD34+ bone marrow cells of MDS patients. Expression profiles were analyzed in relation to different aspects of the disease (i.e., diagnosis, disease subtypes, cytogenetic and mutational aberrations, and risk of progression). LncRNA-PCG networks were constructed to link deregulated lncRNAs with regulatory mechanisms associated with MDS. RESULTS: we found several lncRNAs strongly associated with disease pathogenesis (e.g., H19, WT1-AS, TCL6, LEF1-AS1, EPB41L4A-AS1, PVT1, GAS5, and ZFAS1). Of these, downregulation of LEF1-AS1 and TCL6 and upregulation of H19 and WT1-AS were associated with adverse outcomes in MDS patients. Multivariate analysis revealed that the predominant variables predictive of survival are blast count, H19 level, and TP53 mutation. Coexpression network data suggested that prognosis-related lncRNAs are predominantly related to cell adhesion and differentiation processes (H19 and WT1-AS) and mechanisms such as chromatin modification, cytokine response, and cell proliferation and death (LEF1-AS1 and TCL6). In addition, we observed that transcriptional regulation in the H19/IGF2 region is disrupted in higher-risk MDS, and discordant expression in this locus is associated with worse outcomes. CONCLUSIONS: we identified specific lncRNAs contributing to MDS pathogenesis and proposed cellular processes associated with these transcripts. Of the lncRNAs associated with patient prognosis, the level of H19 transcript might serve as a robust marker comparable to the clinical variables currently used for patient stratification.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Krejcik, Zdenek $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
700    1_
$a Klema, Jiri $u Department of Computer Science, Czech Technical University, 121 35 Prague, Czech Republic.
700    1_
$a Loudova, Nikoleta $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
700    1_
$a Hrustincova, Andrea $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic. Faculty of Science, Charles University, 128 00 Prague, Czech Republic.
700    1_
$a Belickova, Monika $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
700    1_
$a Hruba, Monika $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic. First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic.
700    1_
$a Vesela, Jitka $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
700    1_
$a Stranecky, Viktor $u First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic.
700    1_
$a Kundrat, David $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
700    1_
$a Pecherková, Pavla, $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic. $d 1980- $7 ctu2013787641
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
700    1_
$a Jonasova, Anna $u General University Hospital, 128 08 Prague, Czech Republic.
700    1_
$a Dostalova Merkerova, Michaela $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 10 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32977510 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20231102133358 $b ABA008
999    __
$a ind $b bmc $g 1591329 $s 1112292
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 10 $e 20200923 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 17-31398A $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a 20-19162S $p Grantová Agentura České Republiky
GRA    __
$a 00023736 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace